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ABSTRACT (words = 246) 
 
Purpose: The trabecular bone score (TBS) is an index of bone microarchitecture, independent 
of bone mineral density (BMD), calculated from antero-posterior spine DXA scans. The 
potential role of TBS for monitoring treatment response with bone active substances is not 
established. The aim of this study was to compare the effects of recombinant human 1-34 
parathyroid hormone (teriparatide) and the bisphosphonate ibandronate (IBN), on lumbar 
spine (LS) BMD and TBS in postmenopausal women with osteoporosis. 
 
Methods: Two patient groups with matched age, BMI, and baseline LS BMD, treated with 
either daily subcutaneous teriparatide (N=65) or quarterly intravenous IBN (N=122) during 2 
years and with available LS BMD measurements at baseline and two years after treatment 
initiation were compared.  
 
Results: Baseline characteristics (overall mean ± SD) were similar between groups in terms 
of age, 67.9± 7.4 years; body mass index, 23.8 ± 3.8 kg/m2; BMD L1-L4, 0.741 ± 0.100 
g/cm2 and TBS, 1.208 ± 0.100. Over 24 months, teriparatide induced a significantly larger 
increase in LS BMD and TBS than IBN (+7.6% ± 6.3 vs. +2.9% ± 3.3 and +4.3% ± 6.6 vs. 
+0.3% ± 4.1, respectively; p < 0.0001 for both). LS BMD and TBS were only weakly 
correlated at baseline (r2 = 0.04) with no correlation between the changes in BMD and TBS 
over 24 months. 
 
Conclusions: In postmenopausal women with osteoporosis, a 2-year treatment with 
teriparatide led to a significantly larger increase in LS BMD and TBS than IBN, suggesting 
that teriparatide had more pronounced effects on bone microarchitecture than IBN. 
 
KEY WORDS: osteoporosis, parathyroid hormone, teriparatide, bone mineral density, 
trabecular bone score, treatment, open-label study 
 
MINI ABSTRACT 
Treatment effects over two years of teriparatide versus ibandronate in postmenopausal women 
with osteoporosis were compared using lumbar spine BMD and trabecular bone score (TBS). 
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Teriparatide induced larger increases in BMD and TBS compared to ibandronate suggesting a 
more pronounced effect on bone microarchitecture of the bone anabolic drug. 
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INTRODUCTION:  
Osteoporosis and osteoporosis-related fractures represent a worldwide disease burden, 
especially in North America and Europe [1-5]. With much of this burden stemming from the 
morbidity and mortality related to the roughly nine million osteoporotic fractures that occur 
each year [4, 5], the primary goal of treatment has long been fracture prevention [6-8].  
 
As recommended by the World Health Organization (WHO) since 1994 [9], bone mineral 
density (BMD), measured by dual x-ray absorptiometry (DXA), is the current gold standard 
for diagnosing osteoporosis and monitoring treatment, supported by the fact that BMD is a 
major determinant of bone strength and fracture risk [10]. However, considerable overlap 
exists between BMD values in individuals who develop fractures and those who do not [11], 
indicating that other factors influence both bone strength and fracture risk. To cite just but a 
few: macro-geometry of cortical bone, micro-architecture of trabecular bone, as well as bone 
micro-damage, mineralization, and turnover [12-14].  
 
The trabecular bone score (TBS) is derived from a simple antero-posterior LS DXA scan and 
can be used for the non-invasive assessment of intravertebral cancellous bone 
microarchitecture [15-18]. The TBS was shown to discriminate between patients with incident 
hip, non-vertebral or vertebral fracture and non-fractured patients with osteoporosis in several 
prospective and retrospective cohort studies [19-24], with odds ratios ranging between 1.6 and 
2.05 with a similar order of magnitude than lumber spine BMD [19, 21, 22, 24]. In addition, 
in these studies, the combination of TBS and lumbar spine BMD (LS BMD) was generally 
superior to either measurement alone with regard to fracture risk prediction [19, 20, 22-24]. 
Furthermore, the TBS was responsive to treatment with antiresorptive drugs in a large cohort 
study [25] and in the retrospective analysis of a randomized placebo-controlled trial with the 
aminobisphosphonate zoledronate [26].  
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Daily subcutaneous injections of recombinant human 1-34 N-terminal fragment of 
parathyroid hormone (teriparatide) were shown to increase BMD and to reduce the risk of 
new vertebral and non-vertebral, but not hip, fractures in patients with postmenopausal and 
glucocorticoid-induced osteoporosis [27, 28]. The observed increases in LS BMD with 
teriparatide accounted for approximately 30-41% of the achieved vertebral fracture risk 
reduction, suggesting other mechanisms accounting for the remainder [27, 29]. Teriparatide 
was recently shown to improve trabecular microarchitecture in iliac crest bone biopsies of 
postmenopausal women [29], confirming earlier preclinical data showing improved 
histomorphometric cancellous bone parameters and vertebral bone strength in ovariectomized 
rats [30] and monkeys [31]. The effects of teriparatide on the TBS are unknown. 
 
Bisphosphonates, such as the aminobisphosphonate ibandronate (IBN), are inhibitors of bone 
resorption belonging to the mainstay of osteoporosis treatment. Histomorphometric data in 
postmenopausal women treated during two years with intravenous ibandronate showed no 
increase in trabecular number or volume and no decrease in inter-trabecular separation [32]. 
In line with these findings, an earlier study performed with the intravenous 
aminobisphosphonate zoledronate in postmenopausal women showed an only modest increase 
in TBS consistent with a preservation of vertebral bone micro-architecture [26]. 
 
The aims of this study were: (1) to compare the effects of subcutaneous teriparatide and 
intravenous ibandronate on LS BMD and TBS in postmenopausal women with osteoporosis; 
(2) to assess whether the changes in TBS are independent of those of BMD; and (3) to 
evaluate the changes in TBS in terms of possible clinical relevance at the individual patient 
level. 
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MATERIALS AND METHODS:  
The study was conducted at the Department of Osteoporosis of the University Hospital of 
Berne, Switzerland as an open-label, retrospective, non-randomised, treatment-controlled 
study comparing the effects of an up to 2-year treatment with subcutaneous teriparatide 
(Forsteo®, Eli Lilly, USA) vs. a 2-year treatment with intravenous IBN (Bonviva®, 
Roche, Switzerland) on LS BMD and TBS in two groups of postmenopausal women with 
osteoporosis matched for age, BMI, and LS BMD.  
Study population and treatment schemes 
Postmenopausal women with primary osteoporosis referred for evaluation to the osteoporosis 
consultation of the Department of Osteoporosis of University Hospital of Berne, Switzerland, 
between 2007 and 2009 who were subsequently treated with teriparatide 20μg   self-injected 
daily were evaluated if they had LS BMD measurements performed by DXA at baseline and 
after 2 years of therapy (n=70). Women treated with teriparatide usually had experienced a 
vertebral fragility fracture during a prior therapy with an antiresorptive, independently of their 
LS BMD value. The reimbursed duration of treatment with teriparatide was increased 
from 18 to 24 months during the course of the study. As a consequence, one sixth of the 
patients treated with teriparatide were treated during 18 months followed by an 
intravenous infusion of zoledronate 5mg, the other five sixth were on teriparatide during 
24 months. The control group consisted of postmenopausal women with primary osteoporosis 
in whom a treatment with intravenous ibandronate 3mg every 3 months was initiated between 
2007 and 2009 and monitored during at least two following years at the Department of 
Osteoporosis of Berne. Women treated with ibandronate usually had a BMD T-score at or 
below -2.5 or one or more prevalent vertebral fractures. Women on ibandronate were matched 
for age, BMI, and LS BMD with women in the teriparatide group, following a 2:1 ratio 
(n=140). All subjects were vitamin D-replete and received adequate calcium and vitamin D3 
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supplementation. Women currently on glucocorticoids or presenting other secondary forms of 
osteoporosis were not eligible. Prior therapies with bisphosphonates, estrogens, or other bone 
active substances, including vitamin D were allowed. Only women with evaluable DXA 
scans for both LS BMD and TBS at baseline and after two years in the teriparatide and 
the ibandronate groups, respectively, were included in the analysis. 
 
Measurement of bone mineral density (BMD) 
Bone mineral density was assessed by DXA (Hologic QDR 4500A®, Hologic, Bedford, MA, 
USA) at the single study centre of the Department of Osteoporosis of the University Hospital 
of Berne, Switzerland. All DXA scans were performed in accordance with manufacturer 
recommendations. Lumbar spine BMD measurements were recorded for L1 through L4 (L1-
4). BMD was expressed as grams per square centimeter of hydroxyapatite and as T-scores 
(standard deviation [SD] from the mean of a healthy young female population). The 
manufacturer’s  normative  database was used as reference for the LS after analysis according 
to International Society for Clinical Densitometry (ISCD) rules [33]. Individual vertebrae 
were excluded in case of fractures or degenerative changes, in accordance with ISCD rules for 
individual vertebrae exclusion (more than 1 standard deviation from immediately adjacent 
vertebrae). Quality control was performed daily (anthropometric spine phantom supplied by 
the manufacturer). 
 
Measurement of trabecular bone score (TBS) 
The trabecular bone score (TBS) is a grey-level texture measurement that can be applied to 
DXA images for quantifying local variations in grey level [15-17]. Using experimental 
variograms of 2D projection images, TBS can differentiate between 3-dimensional (3D) 
micro-structures that exhibit the same bone density, but different trabecular characteristics 
[15, 18]. The TBS is obtained by direct (re-)analysis of an acquired lumbar spine DXA image, 
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without need for further imaging. All TBS determinations were performed in a blinded 
manner within the Bone Disease Unit at the University Hospital of Lausanne, Lausanne, 
Switzerland using TBS iNsight® Software version 1.8.2 (Med-Imaps, Bordeaux, France). 
Lumbar spine TBS (LS TBS) was evaluated in the same vertebrae and regions of 
measurement as those used for LS BMD, with LS TBS calculated as the mean value of the 
individual measurements for vertebrae L1-L4. The coefficient of variation for LS BMD 
measurements at the Department of Osteoporosis of the University Hospital of Berne is 
0.90% when applying with ISCD recommendations (15 outpatients representative of our daily 
routine with triplicate measurements after repositioning) with a corresponding coefficient of 
variation of 1.12% for TBS. Thus, the Least Significant Change (LSC) is 2.49% for LS BMD 
and 3.10% for TBS.  
 
Statistical analysis 
Descriptive analysis included means and percentages with standard deviations.  The percent 
changes in BMD and TBS were calculated for each subject as the absolute change from 
baseline to two-year follow-up, divided by the baseline value. Bivariate inter-group 
comparisons were performed between those treated with IBN vs. teriparatide using  Student’s  
t-tests   and   Pearson   χ2   analysis   for   continuous   and   non-continuous variables, respectively. 
Pearson correlation coefficients were calculated for BMD vs. TBS and for change from 
baseline in BMD vs. change from baseline in TBS. All inferential tests were two-tailed and p 
< 0.05 was set as the threshold for statistical significance. All statistical analyses were 
performed using Stata® software (Version 12, StataCorp LP., Texas, USA). 
 
RESULTS  
Overall, 65 (93%) and 122 (87%) patients with evaluable DXA scans for LS BMD and TBS 
at baseline and after two years in the teriparatide and the ibandronate groups, respectively, 
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were included in the analysis. In total, 40%, 40%, and 20% of the patients had 4, 3, and 2 
vertebrae evaluated, respectively. As a result of matching, baseline characteristics (mean ± 
SD) were similar between groups in term of age, body mass index, baseline LS BMD T-score 
and LS TBS (Table 1). Patients in the teriparatide group were more likely having had prior 
therapy with a bisphosphonate (95.4% vs. 80.3%, p=0.005), having prevalent vertebral 
fractures or a positive history of fracture during adulthood (90.5% vs. 44.3% and 73.8% vs. 
41.0%, respectively; p=0.0001 for both), and had a significantly higher clinical fracture risk 
score for hip and major osteoporotic fractures assessed by FRAX®.  
As shown in figure 1, after 24 months of therapy, LS BMD and TBS increased significantly 
more with teriparatide compared to IBN (+7.6% ± 6.3 vs. +2.9% ± 3.3 and +4.3% ± 6.6 vs. 
+0.3% ± 4.1, respectively; p < 0.0001 for both). Compared to baseline, increases in LS BMD 
were significant in both the teriparatide and IBN group (p<0.0001 for both) while increases in 
LS TBS were significant in the teriparatide group only (p< 0.0001). 
Baseline spine BMD and TBS were only weakly correlated, (r2 = 0.04), indicating that only 
4% of the variance in one parameter was explained by the other. There was no correlation 
between the 2-year changes in BMD and TBS from baseline (r2 = 0.01).  
As shown in table 2, LS BMD was more sensitive than LS TBS with regard to the proportion 
of patients achieving an increase above least significant change (LSC) in both treatment 
groups: 78.5% vs. 61.5% (McNemar-test p<0.01) and 51.6% vs. 26.3% (p<0.001) with 
teriparatide and IBN, respectively. Interestingly, while only 11.0% of the patients did not 
respond in terms of TBS below the LSC with teriparatide, this proportion reached 27.0% with 
IBN. Furthermore, in the teriparatide group, 51.0% of the patients were above the LSC for 
both LS BMD and TBS vs. only 28.0% in the IBN group (results not shown in table 2), 
suggesting a stronger effect on bone micro-architecture with the former than with the latter.  
 
DISCUSSION 
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In postmenopausal women with primary osteoporosis, a 2-year treatment with teriparatide 
increased LS BMD and TBS significantly more and in a significantly greater proportion of 
patients than a 2-year treatment with intravenous ibandronate. As the increase in LS TBS was 
largely independent from the BMD response, these results suggests that LS TBS may 
contribute to assess the effects of bone anabolic agents on vertebral micro-architecture.  
 
Only few studies have investigated the effect of bone active substances on LS TBS [25, 26]. 
Taken together with the present findings, these earlier reports are consistent with the concept 
that bisphosphonates allow for “positive  maintenance”  of  bone micro-architecture rather than 
a major improvement in micro-architecture. For almost two decades, bisphosphonates have 
been the therapy of choice to treat osteoporosis and to prevent fractures, relying on solid 
evidence with regard to fracture risk reduction [2, 34-38]. However, the long-term bone safety 
of bisphosphonates has been recently questioned [39]. On one hand, bisphosphonates increase 
bone strength by increasing the mineralization of remodelled bone units, reducing cortical 
porosity and decreasing focal stress. On the other hand, they suppress the generation of new 
bone remodelling units and reduce bone turnover [39]. In the present study, the increase in LS 
BMD and TBS observed with IBN was of a lower order of magnitude than expected. In 
earlier studies, LS TBS increased by 0.25 to 0.5% per year under antiresorptive therapy [25, 
26], which is clearly more than the 0.3% over two years reported in the present study. One of 
the possible explanations may be related to the fact that more than 80% of the “real  life”  
women included had been on bisphosphonate therapy before being switched to intravenous 
ibandronate after a very short or no washout period. This suggests not unexpectedly that, in 
patients under prior antiresorptive therapy, bisphosphonates may be more likely to maintain 
than to restore vertebral microarchitecture. 
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Teriparatide exerts primarily bone anabolic effects, which include increasing cancellous bone 
volume and connectivity, increasing cortical bone thickness, and enhancing trabecular 
morphology [39, 40]. Since the inaugural publication by Neer et al in 2001 [27], several 
smaller studies have confirmed that teriparatide allows for strong BMD increases and for 
fracture risk reduction, suggesting that it may become an attractive alternative to 
bisphosphonates for strengthening and possibly restoring bone microarchitecture [41-44]. In 
the present study, a 2-year therapy with subcutaneous teriparatide induced a statistically 
significant increase in LS BMD and TBS of large magnitude. The latter (+4.3% in only two 
years) exceeds by far the TBS increases reported with antiresorptive substances to date [25, 
26]. Furthermore, the ratio of BMD to TBS increase was approximately 2:1 with teriparatide 
and 9:1 with ibandronate in the present study, compared to 10:1 with bisphosphonates in a 
retrospective study of 534 postmenopausal women treated with antiresorptive therapy in the 
Canadian province of Manitoba [25], and 4:1 in a 3-year randomized controlled study with 
yearly intravenous zoledronate [26]. Taken together with the absence of a significant 
correlation between changes from baseline in BMD and changes from baseline in TBS [25, 
26], these observations indicate that BMD and TBS measure different characteristics of bone 
and bone strength.  
 
With regard to individual therapy monitoring, only 12-35% of patients on bisphosphonates 
had an increase in TBS that was exceeding the LSC in earlier studies [25, 26], as compared to 
26% in the present analysis. In contrast, about 62% of the patients on teriparatide were above 
LSC, primarily indicating that LS TBS may be more suitable for monitoring the effects of 
bone anabolic substances than for monitoring the effects of antiresorptives. 
 
To date, only one direct comparison between teriparatide and a bisphosphonate (risedronate) 
has been published in postmenopausal women with osteoporotic spine compression fractures. 
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In that study, teriparatide yielded a significantly greater increase in BMD from baseline in the 
lumbar spine and femoral neck, and was associated with a lower incidence of vertebral 
fractures at 18 months (4% versus 9%, respectively; p  =  0.01) and with less severe 
vertebral fractures (p  =  0.04) [45]. There have, on the other hand, been several studies 
assessing the effects of teriparatide in patients in whom bisphosphonate treatment has failed 
or otherwise been terminated. In the most recently-published study, post-menopausal women 
with severe osteoporosis who had failed treatment with a bisphosphonate responded well to 
18 months of treatment with daily parathyroid hormone, with a 37% reduction in the 
incidence of fractures in their second year of treatment relative to their first 6 months of 
therapy, and a 76% reduction relative to baseline subsequent to this. Patients also reported 
reduced back pain and improved health-related quality of life while taking teriparatide [46]. 
These results are consistent with the results of several prior studies demonstrating some 
benefit of parathyroid hormones in the aftermath of bisphosphonate therapy [41, 44, 47] 
although it is the first time that results are reported with TBS. 
The findings of the present study are limited by the retrospective nature of the analysis. 
Pretreatment with antiresorptives may have partially blunted some of the expected effects on 
LS BMD and TBS. In addition, the two groups were not comparable with respect to 
osteoporosis severity, which may have influenced the results. Keeping these limitations in 
mind, the results show for the first time that larger effects on trabecular microarchitecture 
assessed by TBS may be expected when using bone anabolic substances and may open the 
way for future research in this direction including, but not limited to, the place of TBS alone 
and/or in combination with BMD and/or clinical risk factors for the choice and monitoring of 
treatments with bone active substances and the identification of more individualized treatment 
schemes for patients with osteoporosis at increased risk of fracture. 
 
CONCLUSIONS 
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In women with postmenopausal osteoporosis, a 2-year treatment with teriparatide exerted 
more beneficial effects on lumbar spine BMD and microarchitecture assessed by TBS than 
ibandronate. Changes in LS BMD and TBS from baseline were not correlated, confirming that 
these two parameters measure different responses of bone to therapy. At the individual patient 
level, TBS was significantly more sensitive to bone anabolic substances than to 
antiresorptives, with almost two thirds of the patients on teriparatide showing TBS increases 
above the least significant change. 
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Figure legends 
Figure 1 
Percent change in lumbar spine BMD and TBS at month 24 after treatment with 
teriparatide (22.9 months) and ibandronate (24 months).  
Mean values ± standard deviation 
p values above the bars refer to significance vs. baseline. 
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Table 1: Baseline Demographics and Clinical Characteristics (mean ± SD) 
 
 
 Teriparatide 
Group 
IBN Group P value 
N  65 122  
Duration of active treatment (months) 22.9 ± 3.6 24.0 ± 4.7 0.10 
Age (years) 68.9 ± 9.0 67.4 ± 6.5 0.20 
BMI (kg/m2) 23.7 ± 4.2 23.8 ± 3.5 0.92 
Prior therapy with an oral / IV 
bisphosphonate (%) 
 
95.4 
 
80.3 
 
0.005 
Duration of washout prior to study drug 
initiation (months) 
 
0.23 ± 0.79 
 
0.26 ± 0.85 
 
0.23 
Lumbar spine 
BMD (g/cm2) 
 
0.759 ± 0.153 
 
0.732 ± 0.080 
 
0.12 
T-score -2.66 ± 1.35 -2.77 ± 0.67 0.46 
TBS 1.206 ± 0.100 1.209 ± 0.100 0.85 
Total hip  
BMD (g/cm2) 
 
0.703 ± 0.113 
 
0.729 ± 0.100 
 
0.10 
T-score -1.96 ± 0.93 -1.75 ± 0.78 0.11 
Femoral neck 
BMD (g/cm2) 
 
0.606 ± 0.105 
 
0.622 ± 0.084 
 
0.27 
T-score -2.09 ± 1.17 -2.11 ± 0.81 0.91 
Prevalent vertebral fractures (%) 90.5 44.3 0.0001 
Positive history of non-vertebral fractures 
during adulthood (%) 
73.8 41 0.0001 
Past use of glucocorticosteroids (%) 9% 4.6% 0.28 
10-year absolute risk for major osteoporotic 
fractures (FRAX® with BMD, %) 
26.7 ± 10.4 21.1 ± 10.1 0.0001 
10-year absolute risk for hip fractures 
(FRAX® with BMD, %) 
8.15 ± 6.7  5.1 ± 5.1  0.0001 
All values are means ± SD, except indicated otherwise 
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Table 2: Percentage of patients above, within and below the least significant change 
(LSC) for both teriparatide and IBN groups and for lumbar spine (LS) BMD and TBS 
 
 Above LSC (%) Within LSC (%) Below LSC (%) 
Teriparatide    
LS BMD 78.5 20.0 1.5 
LS TBS 61.5 27.7 10.8 
Ibandronate    
LS BMD 51.6 42.6 5.8 
LS TBS 26.3 46.7 27.0 
Within LSC for LS BMD is between -2.49% and +2.49% 
Within LSC for LS TBS is between -3.10% and +3.10% 
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